ENYO Pharma receives a €2.5 million grant from EU under the Horizon2020/SME Instrument Phase 2 programme for its project MIMESIS

Published on 06/12/2016

Lyon, December 5, 2016 – ENYO Pharma, a biopharmaceutical company currently focused on developing treatments for viral infections, today announced that it has received a grant of €2.5 million in response to its application to the highly competitive SME Instrument Phase 2 funding programme (6% success rate).

Read next in 'Press releases'

• ENYO Pharma appoints Jeff George as Chairman to support next phase of growth and Phase 3 readiness
• ENYO Pharma nomme Jeff George Président du Conseil d’Administration pour soutenir sa prochaine phase de croissance et la préparation à la Phase 3
• ENYO Pharma announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
• ENYO Pharma annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
• ENYO Pharma annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1